Author: Brett J Skinner, Ph.D.
Like several other countries around the world, Canada has a quasi-regulatory process of health technology assessment (HTA) to evaluate the cost-effectiveness of new drugs and medical devices, in order to make evidence-based recommendations regarding reimbursement of these medical technologies by the publicly funded health care system. The number of experts and the type of expertise employed by HTA agencies varies by jurisdiction. The purpose of this study is to compare the supply of expertise employed by the various HTA advisory committees in Canada relative to the United Kingdom and Australia; and relative to the demand for expertise.
Contains consecutive English and French language versions.
